Henrietta Lacks’s family sues another pharmaceutical company
By Clarence Williams,
The Washington Post
| 08. 10. 2023
The heirs of Henrietta Lacks, the Black woman who died in the 1950s and whose cells have been reproduced for decades in scientific research, filed suit Thursday in Baltimore federal court alleging that a pharmaceutical company profited from using cells without the consent of Lacks or her family.
The action comes almost two weeks after Lacks’s descendants settled litigation with another biotech company that had allegedly profited from the cells despite knowing that they were extracted without her consent. Terms of the litigation were not released.
Thursday’s suit asks a court to force Ultragenyx, a California-based company that focuses on the development and commercialization of products for rare and genetic diseases, to stop the use of Lacks’s cell line without the permission of her family; to create a “trust” for the cells in possession; to reveal the profits earned from use of the cells; and to provide financial relief.
Lacks was a Baltimore mother of five when she was diagnosed with cervical cancer in 1951 at age 31. A Johns Hopkins Hospital doctor took a sample from her tumor without...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...